FRIDAY, Dec. 18 (HealthDay News) -- The benefit of aspirin for the primary prevention of cardiovascular events and death appears to be similar in people with and without diabetes, according to research published in the December issue of Diabetes Care.
Andrew D. Calvin, M.D., of the Mayo Clinic in Rochester, Minn., and colleagues included eight randomized controlled trials -- which enrolled patients with diabetes and no history of stroke or myocardial infarction -- for meta-analysis.
In patients with or without diabetes, the researchers found the relative risk of aspirin versus control for death, myocardial infarction, and stroke to be generally insignificant, save for a significant overall reduction in myocardial infarction. However, further analysis suggested that the effect of aspirin was not significantly different between patients with or without diabetes.
"The decision to use aspirin for primary prevention in individual patients with diabetes remains a complex issue," the authors write. "While there are insufficient data among patients with diabetes to conclusively show a benefit of aspirin therapy for the primary prevention of cardiovascular events, our data suggest, but do not confirm, that the relative benefit of aspirin is similar in patients with and without diabetes."
Abstract
Full Text (subscription or payment may be required)
